Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD

By sjmartinez • February 13, 2025

Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27. PMID: 39197510.

Tags: COPD, ensifentrine, exacerbation, patient-reported outcomes, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Moderators of the Effects of Telehealth Mindfulness-based Interventions for Chronic Pain: A Secondary Responder Analysis of the LAMP Randomized Controlled Trial

Calvert CM, Hagel Campbell EM, Cross LJS, Bangerter A, Bronfort G, Evans R, Meis LA, Haley A, Leininger B, Matthias M, Polusny M, Allen K,[...]

Leveraging scholarship to lead

Moriates C. Leveraging scholarship to lead. J Hosp Med. 2026 Sep 9. doi: 10.1002/jhm.70478. Epub ahead of print. PMID: 42717657.

Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension

Alotaibi M, Tang A, Sun N, Gurholt I, Yuguchi E, Roberts K, Preston I, Warburton R, Yuan JX, Kim NH, Chan SY, Jain M, Cheng[...]